Synopsis:
Bliss GVS Pharma Ltd Q1 revenue rose 13% to Rs. 207 Crores YoY, and net profit grew 167% to Rs. 44.4 Crores QoQ.
The shares of a Small-Cap company, specializing in manufacturing, marketing, trading, and export of pharmaceutical formulations, jumped upto 17 percent upon declaring Q1 results with a 167 percent rise in profit Quarter on Quarter (QoQ).
With a market capitalization of Rs. 1,886.82 crores on Wednesday, the shares of Bliss GVS Pharma Ltd jumped upto 17 percent, making a high of Rs. 182.25 per share compared to its previous closing price of Rs. 155.65 per share.
Bliss GVS Pharma Ltd, engaged in manufacturing, marketing, trading, and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups, has announced its Q1 results as follows.
Its Revenue from operations rose by 13 percent YoY from Rs. 184 Crores in Q1FY25 to Rs. 207 Crores in Q1FY26, and it rose by 5 percent QoQ from Rs. 198 Crores in Q4FY25 to Rs. 207 Crores in Q1FY26.
Its Net Profit YoY rose by 108 percent from Rs. 22.1 Crores in Q1FY25 to Rs. 44.4 Crores in Q1FY26, and it rose by 167 percent QoQ from a profit of Rs. 16.6 Crores in Q4FY25 to Rs. 44.4 Crores in Q1FY26. The earnings per share (EPS) for the quarter stood at Rs. 4.08, compared to Rs. 1.47 in the previous quarter.
The company has a strong financial position, with a low P/E ratio of 19.48 compared to the industry average of 33.61, indicating it may be undervalued. It maintains a low debt-to-equity ratio of 0.08 and has sufficient current assets to cover its liabilities. Additionally, it has shown impressive performance with an average net profit growth of 52.23% over the past three years.
Company Overview & Others
Bliss GVS Pharma Limited, established in 1984 and headquartered in Mumbai, specializes in developing, manufacturing, and marketing pharmaceutical formulations. They are considered world leaders in Suppositories and Pessaries dosage forms.
Their product range includes various dosage forms such as capsules, creams, gels, and tablets, among others, covering therapeutic areas like anti-malarial, anti-fungal, and anti-bacterial segments.
It markets its products in over sixty countries, with a strong presence in African anti-malarial markets. Their manufacturing plants hold certifications like EU GMP, WHO GMP, and ISO standards. The company is also expanding its capabilities and engaging in environmentally friendly processes and community initiatives.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
